Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Ruxolitinib-intolerant Intermediate-2/High-risk Myelofibrosis
CTR20192225Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), myelofibrosis (MF), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Nov 2019; status: completed.
02
Drugs
jaktinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20192225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192225.